Skip to main content

Table 1 Baseline characteristics of CDSS art patients by site type, n = 5901

From: A clinical decision support system is associated with reduced loss to follow-up among patients receiving HIV treatment in Kenya: a cluster randomized trial

Characteristic Control Intervention Total P value
Unweighted n Weighted % 95% CI Unweighted n Weighted % 95% CI Unweighted N Weighted % 95% CI
Age group, years            < .001
< 10 years 303 8.4 (7.5–9.3) 170 7.4 (6.3–8.4) 473 8 (7.3–8.7)  
10–19 years 128 3.6 (3.0–4.2) 82 3.6 (2.8–4.3) 210 3.6 (3.1–4.0)  
20–29 years 1065 29.6 (28.1–31.1) 638 27.7 (25.8–29.5) 1703 28.9 (27.7–30.0)  
30–39 years 1169 32.5 (31.0–34.0) 766 33.2 (31.3–35.1) 1935 32.8 (31.6–34.0)  
40–49 years 610 17 (15.7–18.2) 359 15.6 (14.1–17.0) 969 16.4 (15.5–17.4)  
50–59 years 251 7 (6.1–7.8) 210 9.1 (7.9–10.3) 461 7.8 (7.1–8.5)  
60 + years 69 1.9 (1.5–2.4) 81 3.5 (2.8–4.3) 150 2.5 (2.1–2.9)  
Total 3595 100 (–) 2306 100 (–) 5901 100 (–)  
Sex           0.055
Male 1311 36.5 (34.9–38.0) 898 38.9 (37.0–40.9) 2209 37.4 (36.2–38.7)  
Female 2284 63.5 (62.0–65.1) 1408 61.1 (59.1–63.0) 3692 62.6 (61.3–63.8)  
Total 3595 100 (–) 2306 100 (–) 5901 100 (–)  
Marital status            < .001
Missing 309 8.6 (7.7–9.5) 202 8.8 (7.6–9.9) 511 8.7 (7.9–9.4)  
Married 1934 53.8 (52.2–55.4) 1163 50.4 (48.4–52.5) 3097 52.5 (51.2–53.8)  
Divorced/separated 138 3.8 (3.2–4.5) 133 5.8 (4.8–6.7) 271 4.6 (4.1–5.1)  
Widow 673 18.7 (17.4–20.0) 401 17.4 (15.8–18.9) 1074 18.2 (17.2–19.2)  
Single 541 15 (13.9–16.2) 407 17.6 (16.1–19.2) 948 16.1 (15.1–17.0)  
Total 3595 100 (–) 2306 100 (–) 5901 100 (–)  
CD4 category            < .001
Missing 846 23.5 (22.1–24.9) 727 31.5 (29.6–33.4) 1573 26.7 (25.5–27.8)  
< 200 1592 44.3 (42.7–45.9) 900 39 (37.0–41.0) 2492 42.2 (41.0–43.5)  
200–349 984 27.4 (25.9–28.8) 620 26.9 (25.1–28.7) 1604 27.2 (26.0–28.3)  
350–500 78 2.2 (1.7–2.6) 33 1.4 (0.9–1.9) 111 1.9 (1.5–2.2)  
≥ 500 95 2.6 (2.1–3.2) 26 1.1 (0.7–1.6) 121 2.1 (1.7–2.4)  
Total 3595 100 (–) 2306 100 (–) 5901 100 (–)  
WHO stage           0.105
Missing 193 5.4 (4.6–6.1) 105 4.6 (3.7–5.4) 298 5 (4.5–5.6)  
WHO I 707 19.7 (18.4–21.0) 487 21.1 (19.5–22.8) 1194 20.2 (19.2–21.3)  
WHO II 1056 29.4 (27.9–30.9) 645 28 (26.1–29.8) 1701 28.8 (27.7–30.0)  
WHO III 1550 43.1 (41.5–44.7) 993 43.1 (41.0–45.1) 2543 43.1 (41.8–44.4)  
WHO IV 89 2.5 (2.0–3.0) 76 3.3 (2.6–4.0) 165 2.8 (2.4–3.2)  
Total 3595 100 (–) 2306 100 (–) 5901 100 (–)  
First line regimen            < .001
Nevirapine 3084 85.8 (84.6–86.9) 1803 78.2 (76.5–79.9) 4887 82.8 (81.9–83.8)  
Efavirenz 489 13.6 (12.5–14.7) 465 20.2 (18.5–21.8) 954 16.2 (15.2–17.1)  
Other 22 0.6 (0.4–0.9) 38 1.6 (1.1–2.2) 60 1 (0.8–1.3)  
Total 3595 100 (–) 2306 100 (–) 5901 100 (–)  
Art adherence           0.012
Missing 3112 86.6 (85.4–87.7) 1934 83.9 (82.4–85.4) 5046 85.5 (84.6–86.4)  
Satisfactory 480 13.4 (12.2–14.5) 368 16 (14.5–17.5) 848 14.4 (13.5–15.3)  
Unsatisfactory 3 0.1 (0.0–0.2) 4 0.2 (0.0–0.3) 7 0.1 (0.0–0.2)  
Total 3595 100 (–) 2306 100 (–) 5901 100 (–)